Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy
分子靶向药物和免疫疗法出现后,晚期或复发性非小细胞肺癌患者发生第二原发性恶性肿瘤的风险增加。
期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.15457
Masui, Yoshihiro; Shukuya, Takehito; Kataoka, Shunichi; Shiozaki, Hitomi; Kurokawa, Kana; Nakamura, Ikuko; Miyawaki, Taichi; Koinuma, Yoshika; Asao, Tetsuhiko; Kanemaru, Ryota; Shimamura, Shoko Sonobe; Mimori, Tomoyasu; Mitsuishi, Yoichiro; Tajima, Ken; Shimada, Naoko; Takahashi, Kazuhisa